icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
 
 
 
Safety, tolerability and pharmacokinetics of JNJ-56136379, a novel HBV capsid assembly modulator, in healthy subjects
 
 
  Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
 
J.Z. Yogaratnam,1J. Vandenbossche,2W. Jessner,2M. Van den Boer,3J. Biewenga,2F. Rasschaert,3C. Vistuer,2K. Janssen,2I. Smyej,2D. Verstraete,2J.M. Berke,2K. Vandyck,2S. Chanda,1J. Fry1
1Alios BioPharma, Inc., South San Francisco, CA, United States; 2Janssen Pharmaceutica NV, Beerse, Belgium; 3Janssen Pharmaceutica NV, Merksem, Belgium

HCV1

HCV2

HCV3

HCV4

HCV5

HCV6

HCV7